Seeking Alpha

Celgene (CELG) and privately held VentiRx sign a deal to develop the latter's VTX-2337 compound...

Celgene (CELG) and privately held VentiRx sign a deal to develop the latter's VTX-2337 compound for the treatment of cancer. Under the agreement, Celgene will pay $35M for further R&D, and will retain the option to make an equity investment in VentiRx or aquire the company.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs